Shanghai Junshi Biosciences Announces Acceptance of NDAs for Subcutaneous Toripalimab Injection Covering 12 Tumor Indications

Shanghai Junshi Biosciences Co., Ltd. (Stock code: 1877) has made a major announcement that could significantly impact its future growth and valuation. The company revealed that the National Medical Products Administration (NMPA) of China has accepted its New Drug Applications (NDAs) for toripalimab injection (subcutaneous injection, code: JS001sc) for 12 tumor indications. This is a voluntary announcement and follows their previous overseas regulatory update on 9 March 2026.

Key Highlights for Investors

• First Domestic Subcutaneous Anti-PD-1 Monoclonal Antibody: JS001sc is the first homegrown anti-PD-1 monoclonal antibody in subcutaneous formulation to reach the marketing application stage in China. This positions Junshi Biosciences as a leader in innovation within the immunotherapy space.
• Broader Indication Coverage: The NDAs cover 12 indications, encompassing all currently approved uses of the original intravenous toripalimab injection in mainland China. This potentially expands the market for JS001sc, allowing the company to capture a broader patient base.
• Convenience for Patients: The subcutaneous formulation offers significant advantages over existing intravenous options, reducing administration times and improving patient convenience—a critical factor in therapy adherence and patient quality of life.

Product and Regulatory Details

• Product Name: Toripalimab Injection (subcutaneous injection, JS001sc)
• Specification: 180 mg (1 ml) in a pre-filled syringe (single dose)
• Acceptance Numbers: CXSS2600035 to CXSS2600047 (12 NDAs in total)
• Application Type: Registration of Domestic Production of Pharmaceutical Product
• Applicant: Shanghai Junshi Biosciences Co., Ltd.

Market Opportunity & Clinical Background

• According to GLOBOCAN 2022 data, there were 4.82 million new cancer cases and 2.57 million cancer-related deaths in China in 2022—demonstrating the substantial market for innovative cancer therapies.
• Immuno-oncology (I-O) therapies, such as anti-PD-1 monoclonal antibodies, are now first-line treatments for various malignancies, including lung, breast, liver, esophageal, and nasopharyngeal cancers. Treatment settings range from adjuvant/neoadjuvant for early-stage disease to first–last line for advanced cancers.
• Most I-O therapies in China are currently administered intravenously, which is time-consuming and inconvenient. Subcutaneous options like JS001sc could address a significant unmet clinical need and drive wider adoption.

Clinical Validation

• The NDAs are supported by the pivotal JS001sc-002-III-NSCLC Study (NCT06505837), a multi-center, open-label, randomized phase III clinical trial led by Prof. Wu Lin at Hunan Cancer Hospital.
• This trial compared exposure, efficacy, and safety of JS001sc (subcutaneous) versus the original JS001 (intravenous) in combination with chemotherapy as first-line treatment for recurrent or metastatic non-squamous non-small-cell lung cancer (NSCLC).
• Key Result: JS001sc demonstrated non-inferior drug exposure and comparable efficacy and safety to JS001, confirming the clinical value of the subcutaneous formulation. Further results will be presented at an upcoming international conference.
• This is the first phase III study of a domestic subcutaneous anti-PD-1 monoclonal antibody in China, highlighting Junshi’s pioneering role.

Potential Impact on Shareholders

• Market Leadership: Acceptance of the NDAs for the first domestic subcutaneous anti-PD-1 mAb could significantly strengthen Junshi’s market position and competitive advantage.
• Commercialization Prospects: If approved, JS001sc could rapidly gain market share due to its patient-friendly formulation, potentially driving revenue growth and enhancing shareholder value.
• Risk Factors: The company highlights the inherent risks and uncertainties in pharmaceutical R&D and commercialization. Investors should be aware that further regulatory review is required, and there is no guarantee of eventual approval or commercial success.
• Disclosure Commitment: Junshi Biosciences has pledged to provide timely updates on project developments in accordance with regulatory requirements—helping investors stay informed about material changes.

Governance and Board Composition

The announcement was authorized by Mr. Xiong Jun (Chairman), and the current board includes a mix of executive, non-executive, and independent non-executive directors, ensuring robust governance practices.

Conclusion for Investors

The acceptance of the NDAs for JS001sc is a significant milestone for Shanghai Junshi Biosciences, potentially opening up new market opportunities and reinforcing the company’s leadership in cancer immunotherapy. This development is price-sensitive and could impact the company’s share value, especially if the new formulation receives final approval and achieves commercial uptake.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Pharmaceutical product development and regulatory approval involve significant risks and uncertainties. Investors are urged to conduct their own due diligence and consult with financial advisors before making investment decisions related to Shanghai Junshi Biosciences or its securities.

View JUNSHI BIO Historical chart here